News stories about Spero Therapeutics (NASDAQ:SPRO) have trended somewhat negative recently, according to Accern Sentiment Analysis. The research group ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Spero Therapeutics earned a news impact score of -0.05 on Accern’s scale. Accern also gave media coverage about the company an impact score of 47.8485078102046 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Shares of Spero Therapeutics (NASDAQ SPRO) traded down $0.10 during midday trading on Friday, reaching $12.25. 18,925 shares of the company traded hands, compared to its average volume of 71,313. The company has a market capitalization of $176.02 and a price-to-earnings ratio of -4.30. Spero Therapeutics has a fifty-two week low of $9.84 and a fifty-two week high of $15.40.
Spero Therapeutics (NASDAQ:SPRO) last released its quarterly earnings data on Thursday, December 14th. The company reported ($36.02) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.43) by ($33.59). The business had revenue of $0.60 million for the quarter, compared to analysts’ expectations of $0.20 million. analysts predict that Spero Therapeutics will post -8.52 EPS for the current fiscal year.
A number of research firms have recently commented on SPRO. Bank of America began coverage on shares of Spero Therapeutics in a research note on Monday, November 27th. They issued a “neutral” rating on the stock. Stifel Nicolaus assumed coverage on shares of Spero Therapeutics in a research note on Monday, November 27th. They set a “buy” rating and a $26.00 target price on the stock. Cowen assumed coverage on shares of Spero Therapeutics in a research note on Monday, November 27th. They set an “outperform” rating on the stock. Finally, Oppenheimer assumed coverage on shares of Spero Therapeutics in a research note on Monday, November 27th. They set a “buy” rating and a $30.00 target price on the stock.
In other Spero Therapeutics news, Director Casper Breum acquired 214,285 shares of the company’s stock in a transaction on Monday, November 6th. The shares were purchased at an average cost of $14.00 per share, with a total value of $2,999,990.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Plc Glaxosmithkline acquired 428,571 shares of the company’s stock in a transaction on Monday, November 6th. The stock was acquired at an average cost of $14.00 per share, for a total transaction of $5,999,994.00. The disclosure for this purchase can be found here. Insiders acquired 649,356 shares of company stock worth $9,090,984 over the last ninety days. Insiders own 13.90% of the company’s stock.
WARNING: “Spero Therapeutics (NASDAQ:SPRO) Earns News Impact Rating of -0.05” was originally posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The correct version of this report can be read at https://www.thelincolnianonline.com/2018/01/13/spero-therapeutics-spro-getting-somewhat-critical-media-coverage-study-shows-updated.html.
About Spero Therapeutics
SmartPros Ltd. is engaged in provision of learning and educational solutions in content areas that target specific markets, including accounting/finance, legal, engineering, securities and insurance. The Company also provides education in banking, finance, taxation, information technology, health and safety, human resources and compliance for the general corporate market.
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.